Multimodal hypoxia imaging and intensity modulated radiation therapy for unresectable non-small-cell lung cancer: the HIL trial

Vasileios Askoxylakis, Julien Dinkel, Monika Eichinger, Bram Stieltjes, Gregor Sommer, Ludwig G Strauss, Antonia Dimitrakopoulou-Strauss, Annette Kopp-Schneider, Uwe Haberkorn, Peter E Huber, Marc Bischof, Jürgen Debus, Christian Thieke, Vasileios Askoxylakis, Julien Dinkel, Monika Eichinger, Bram Stieltjes, Gregor Sommer, Ludwig G Strauss, Antonia Dimitrakopoulou-Strauss, Annette Kopp-Schneider, Uwe Haberkorn, Peter E Huber, Marc Bischof, Jürgen Debus, Christian Thieke

Abstract

Background: Radiotherapy, preferably combined with chemotherapy, is the treatment standard for locally advanced, unresectable non-small cell lung cancer (NSCLC). The tumor response to different therapy protocols is variable, with hypoxia known to be a major factor that negatively influences treatment effectiveness. Visualisation of tumor hypoxia prior to the use of modern radiation therapy strategies, such as intensity modulated radiation therapy (IMRT), might allow optimized dose applications to the target volume, leading to improvement of therapy outcome. (18)F-fluoromisonidazole dynamic positron emission tomography and computed tomography ((18) F-FMISO dPET-CT) and functional magnetic resonance imaging (functional MRI) are attractive options for imaging tumor hypoxia.

Methods/design: The HIL trial is a single centre study combining multimodal hypoxia imaging with (18) F-FMISO dPET-CT and functional MRI, with intensity modulated radiation therapy (IMRT) in patients with inoperable stage III NSCLC. 15 patients will be recruited in the study. All patients undergo initial FDG PET-CT and serial (18) F-FMISO dPET-CT and functional MRI before treatment, at week 5 of radiotherapy and 6 weeks post treatment. Radiation therapy is performed as inversely planned IMRT based on 4D-CT.

Discussion: Primary objectives of the trial are to characterize the correlation of (18) F-FMISO dPET-CT and functional MRI for tumor hypoxia imaging in NSCLC and evaluate possible effects of radiation therapy on tumor re-oxygenation. Further objectives include the generation of data regarding the prognostic value of (18) F-FMISO dPET-CT and functional MRI for locoregional control, progression free survival and overall survival of NSCLC treated with IMRT, which will form the basis for larger clinical trials focusing on possible interactions between tumor oxygenation and radiotherapy outcome.

Trial registration: The ClinicalTrials.gov protocol ID is NCT01617980.

Figures

Figure 1
Figure 1
Trial workflow.

References

    1. Askoxylakis V, Thieke C, Pleger ST, Most P, Tanner J, Lindel K, Katus HA, Debus J, Bischof M. Long-term survival of cancer patients compared to heart failure and stroke: a systematic review. BMC Cancer. 2010;10:105. doi: 10.1186/1471-2407-10-105.
    1. Willner J, Baier K, Caragiani E, Tschammler A, Flentje M. Dose, volume, and tumor control prediction in primary radiotherapy of non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2002;52:382–389. doi: 10.1016/S0360-3016(01)01823-5.
    1. Anderson CS, Curran WJ. Combined modality therapy for stage III non-small-cell lung cancer. Semin Radiat Oncol. 2010;20:186–191. doi: 10.1016/j.semradonc.2010.01.007.
    1. Lee CB, Stinchcombe TE, Moore DT, Morris DE, Hayes DN, Halle J, Rosenman JG, Rivera MP, Socinski MA. Late complications of high dose (>/=66 Gy) thoracic conformal radiation therapy in combined modality trials in unresectable stage III non-small cell lung cancer. J Thorac Oncol. 2009;4:74–79. doi: 10.1097/JTO.0b013e3181915028.
    1. Christian JA, Bedford JL, Webb S, Brada M. Comparison of inverse-planned three-dimensional conformal radiotherapy and intensity-modulated radiotherapy for non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2007;67:735–741. doi: 10.1016/j.ijrobp.2006.09.047.
    1. De Ruysscher D, Nestle U, Jeraj R, Macmanus M. PET scans in radiotherapy planning of lung cancer. Lung Cancer. 2012;75(2):141–145. doi: 10.1016/j.lungcan.2011.07.018.
    1. Yaremko BP, Guerrero TM, Noyola-Martinez J, Guerra R, Lege DG, Nguyen LT, Balter PA, Cox JD, Komaki R. Reduction of normal lung iradiation in locally advanced non-small-cell lung patients, using ventilation images for functional avoidance. Int J Radiat Oncol Biol Phys. 2007;68:562–571. doi: 10.1016/j.ijrobp.2007.01.044.
    1. Ford EC, Mageras GS, Yorke E, Ling CC. Respiration-correlated spiral CT: a method of measuring respiratory-induced anatomic motion for radiation treatment planning. Med Phys. 2003;30:88–97. doi: 10.1118/1.1531177.
    1. Guerrero T, Sanders K, Castillo E, Zhang Y, Bidaut L, Pan T, Komaki R. Dynamic ventilation imaging from four-dimensional computed tomography. Phys Med Biol. 2006;51:777–791. doi: 10.1088/0031-9155/51/4/002.
    1. Fujimoto K. Usefulness of contrast-enhanced magnetic resonance imaging for evaluating solitary pulmonary nodules. Cancer imaging. 2008;3:36–44.
    1. Henzler T, Schmid-Bindert G, Schoenberg SO, Fink C. Diffusion and perfusion MRI of the lung and mediastinum. Eur J Radiol. 2010;76:329–336. doi: 10.1016/j.ejrad.2010.05.005.
    1. Demir R, Naschberger L, Demir I, Melling N, Dimmler A, Papadopoulus T, Sturzl M, Klein P, Hohenberger W. Hypoxia generates a more invasive phenotype of tumour cells: An in vivo experimental setup based on the chorioallantoic membrane. Pathol Oncol Res. 2009;15:417–422. doi: 10.1007/s12253-008-9140-y.
    1. Graves EE, Maity A, Le QT. The tumor microenvironment in non-small-cell lung cancer. Semin Radiat Oncol. 2010;20:156–163. doi: 10.1016/j.semradonc.2010.01.003.
    1. Bussink J, Kaanders JH, van der Kogel AJ. Tumor hypoxia at the micro-regional level: clinical relevance and predictive value of exogenous and endogenous hypoxic cell markers. Radiother Oncol. 2003;67:3–15. doi: 10.1016/S0167-8140(03)00011-2.
    1. Lee ST, Scott AM. Hypoxia positron emission tomography imaging with 18f-fluoromisonidazole. Semin Nucl Med. 2007;37:451–461. doi: 10.1053/j.semnuclmed.2007.07.001.
    1. Zimny M, Gagel B, Dimartino E, Hamacher K, Coenen HH, Westhofen M, Eble M, Buell U, Reinarzt P. FDG-a marker of tumour hypoxia? A comparison with [(18 F]fluoromisonidazole and pO (2)-polarography in metastatic head and neck cancer. Eur J Nucl Med Mol Imaging. 2006;33:1426–1431. doi: 10.1007/s00259-006-0175-6.
    1. Thorwarth D, Eschmann SM, Holzner F, Paulsen F, Alber M. Combined uptake of [18 F]FDG and [18 F]FMISO correlates with radiation therapy outcome in head-and-neck cancer patients. Radiother Oncol. 2006;80:151–156. doi: 10.1016/j.radonc.2006.07.033.
    1. Eschmann SM, Paulsen F, Reimold M, Dittmann H, Welz S, Reischl G, Machulla HJ, Bares R. Prognostic impact of hypoxia imaging with 18 F-misonidazole PET in non-small cell lung cancer and head and neck cancer before radiotherapy. J Nucl Med. 2005;46:253–260.
    1. Gagel B, Reinarzt P, Demirel C, Kaiser HJ, Zimny M, Piroth M, Pinkawa M, Stanzel S, Asadpour B, Hamacher K, Coenen HH, Buell U, Eble MJ. [18 F]fluoromisonidazole and [18 F] fluorodeoxyglucose positron emission tomography in response evaluation after chemo-/radiotherapy of non-small-cell lung cancer: a feasibility study. BMC Cancer. 2006;6:51. doi: 10.1186/1471-2407-6-51.
    1. Pacheco-Torres J, López-Larrubia P, Ballesteros P, Cerdán S. Imaging tumor hypoxia by magnetic resonance methods. NMR Biomed. 2011;24:1–16. doi: 10.1002/nbm.1558.
    1. Dimitrakopoulou-Strauss A, Hoffmann M, Bergner R, Uppenkamp M, Eisenhut M, Pan L, Haberkorn U, Strauss LG. Prediction of short-term survival in patients with advanced nonsmall cell lung cancer following chemotherapy based on 2-deoxy-2-[F-18]fluoro-D-glucose-positron emission tomography: a feasibility study. Mol Imaging Biol. 2007;9:308–317. doi: 10.1007/s11307-007-0103-6.
    1. Lemke A, Laun FB, Simon D, Stieltjes B, Schad LR. An in vivo verification of the intravoxel incoherent motion effect in diffusion-weighted imaging of the abdomen. Magn Reson Med. 2010;64:1580–1585. doi: 10.1002/mrm.22565.
    1. Patel J, Sigmund EE, Rusinek H, Oei M, Babb JS, Taouli B. Diagnosis of cirrhosis with intravoxel incoherent motion diffusion MRI and dynamic contrast- enhanced MRI alone and in combination: preliminary experience. J Magn Reson Imaging. 2010;31:589–600. doi: 10.1002/jmri.22081.
    1. Hintze C, Stemmer A, Bock M, Kuder TA, Risse F, Dinkel J, Prüm H, Puderbach M, Fink C, Biederer J, Kauczor HU. A hybrid breath hold and continued respiration-triggered technique for time-resolved 3D MRI perfusion studies in lung cancer. Rofo. 2010;182:45–52. doi: 10.1055/s-0028-1109713.
    1. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. New guidelines to evaluate the response to treatment in solid tumors. In J Natl Cancer Inst. 2000;92(3):205–216. doi: 10.1093/jnci/92.3.205.
    1. Sura S, Gupta V, Yorke E, Jackson A, Amols H, Rosenzweig KE. Intensity modulated radiation therapy (IMRT) for inoperable non-small cell lung cancer: the Memorial Sloan-Kettering Cancer Center (MSKCC) experience. Radiother Oncol. 2008;87:17–23. doi: 10.1016/j.radonc.2008.02.005.
    1. Jiang ZQ, Yang K, Komaki R, Wei X, Tucker SL, Zhuang Y, Martel MK, Vedam S, Balter P, Zhu G, Gomez D, Lu C, Mohan R, Cox JD, Liao Z. Long-term clinical outcome of intensity-modulated radiotherapy for inoperable non-small-cell lung cancer: The MD Anderson experience. Int J Radiat Oncol Biol Phys. 2012;83:332–339. doi: 10.1016/j.ijrobp.2011.06.1963.
    1. Napadow VJ, Mai V, Bankier A, Gilbert RJ, Edelman R, Chen Q. Determination of regional pulmonary parenchymal strain during normal respiration using spin inversion tagged magnetization MRI. J Magn Reson Imaging. 2001;13:467–474. doi: 10.1002/jmri.1068.
    1. Cho H, Ackerstaff E, Carlin S, Lupu ME, Wang Y, Rizwan A, O’Donoghue J, Ling CC, Humm JZ, Zanzonico PB, Koutcher JA. Noninvasive multimodality imaging of the tumor microenvironment: registered dynamic magnetic resonance imaging and positron emission tomography studies of a preclinical tumor model of tumor hypoxia. Neoplasia. 2009;11:247–259.
    1. Jansen JF, Schöder H, Lee NY, Wang Y, Pfister DG, Fury MG, Stambuk HE, Humm JL, Koutcher JA, Shukla-Dave A. Noninvasive assessment of tumor microenvironment using dynamic contrast-enhanced magnetic resonance imaging and 18 F-fluoromisonidazole positron emission tomography imaging in neck nodal metastases. Int J Radiat Oncol Biol Phys. 2010;77:1403–1410. doi: 10.1016/j.ijrobp.2009.07.009.
    1. Dirix P, Vandecaveye V, De Keyzer F, Stroobants S, Hermans R, Nuyts S. Dose painting in radiotherapy for head and neck squamous cell carcinoma: value of repeated functional imaging with (18)F-FDG PET, (18)F-fluoromisonidazole PET, diffusion-weighted MRI, and dynamic contrast-enhanced MRI. J Nucl Med. 2009;50:1020–1027. doi: 10.2967/jnumed.109.062638.

Source: PubMed

Sponsoren und Mitarbeiter

Krankheiten

Drogeninterventionen

3
Abonnieren